{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:49:15Z","timestamp":1782604155982,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI17C1561"],"award-info":[{"award-number":["HI17C1561"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Revascularization surgery is considered a standard treatment for preventing additional stroke in symptomatic moyamoya disease (MMD). In hemodynamically stable, and asymptomatic or mildly symptomatic patients, however, the treatment strategy is controversial because of the obscure natural course of them. The authors analyzed the benefits and risks of antiplatelet medication in those patients. Medical data were retrospectively reviewed in 439 hemispheres of 243 patients with stable hemodynamic status. Overall, 121 patients (49.8%) with 222 studied hemispheres (50.6%) took antiplatelet medication. Symptomatic cerebral infarction and hemorrhage occurred in 10 (2.3%) and 30 (6.8%) hemispheres, over a mean follow-up of 62.0\u2009\u00b1\u200943.4\u00a0months (range 6\u2013218\u00a0months). The use of antiplatelet agents was statistically insignificant in terms of symptomatic infarction, hemorrhage and improvement of ischemic symptoms. In subgroup analyses within the antiplatelet group according to drug potency and duration of medication, a longer duration of antiplatelet medication significantly improved ischemic symptoms (adjusted OR 1.02; 95% CI 1.01\u20131.03; p\u2009=\u20090.006). Antiplatelet medication failed to prevent symptomatic cerebral infarction or improve ischemic symptoms. However, antiplatelet therapy did not increase the risk of cerebral hemorrhage.<\/jats:p>","DOI":"10.1038\/s41598-021-99009-1","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T10:21:04Z","timestamp":1632910864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Benefits and risks of antiplatelet medication in hemodynamically stable adult moyamoya disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Chang Hwan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Sang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Seung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"99009_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archneur.1969.00480090076012","volume":"20","author":"J Suzuki","year":"1969","unstructured":"Suzuki, J. & Takaku, A. Cerebrovascular, \u201cmoyamoya\u201d disease. Disease showing abnormal net-like vessels in base of brain. Arch. Neurol. 20, 288\u2013299. https:\/\/doi.org\/10.1001\/archneur.1969.00480090076012 (1969).","journal-title":"Arch. Neurol."},{"key":"99009_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S1474-4422(08)70240-0","volume":"7","author":"S Kuroda","year":"2008","unstructured":"Kuroda, S. & Houkin, K. Moyamoya disease: Current concepts and future perspectives. Lancet Neurol. 7, 1056\u20131066. https:\/\/doi.org\/10.1016\/S1474-4422(08)70240-0 (2008).","journal-title":"Lancet Neurol."},{"key":"99009_CR3","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/Strokeaha.118.022490","volume":"50","author":"C Jeon","year":"2019","unstructured":"Jeon, C., Yeon, J. Y., Jo, K. I., Hong, S. C. & Kim, J. S. Clinical role of microembolic signals in adult moyamoya disease with ischemic stroke. Stroke 50, 1130\u20131135. https:\/\/doi.org\/10.1161\/Strokeaha.118.022490 (2019).","journal-title":"Stroke"},{"key":"99009_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1179\/1743132814y.0000000351","volume":"36","author":"JE Kim","year":"2014","unstructured":"Kim, J. E. & Jeon, J. S. An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues. Neurol. Res. 36, 407\u2013416. https:\/\/doi.org\/10.1179\/1743132814y.0000000351 (2014).","journal-title":"Neurol. Res."},{"key":"99009_CR5","doi-asserted-by":"publisher","unstructured":"Research Committee on the Pathology, Treatment of Spontaneous Occlusion of the Circle of, W. & Health Labour Sciences Research Grant for Research on Measures for Infractable, D. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol. Med. Chir. (Tokyo) 52, 245\u2013266. https:\/\/doi.org\/10.2176\/nmc.52.245 (2012).","DOI":"10.2176\/nmc.52.245"},{"key":"99009_CR6","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1161\/Strokeaha.107.513408","volume":"39","author":"M Kraemer","year":"2008","unstructured":"Kraemer, M., Heienbrok, W. & Berlit, P. Moyamoya disease in Europeans. Stroke 39, 3193\u20133200. https:\/\/doi.org\/10.1161\/Strokeaha.107.513408 (2008).","journal-title":"Stroke"},{"key":"99009_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2176\/nmc.52.311","volume":"52","author":"JE Kim","year":"2012","unstructured":"Kim, J. E. et al. Clinical features of adult moyamoya disease with special reference to the diagnosis. Neurol. Med. Chir. (Tokyo) 52, 311\u2013317. https:\/\/doi.org\/10.2176\/nmc.52.311 (2012).","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"99009_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3171\/2014.9.Jns132281","volume":"122","author":"WS Cho","year":"2015","unstructured":"Cho, W. S. et al. The natural clinical course of hemodynamically stable adult moyamoya disease. J. Neurosurg. 122, 82\u201389. https:\/\/doi.org\/10.3171\/2014.9.Jns132281 (2015).","journal-title":"J. Neurosurg."},{"key":"99009_CR9","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1056\/NEJMra0804622","volume":"360","author":"RM Scott","year":"2009","unstructured":"Scott, R. M. & Smith, E. R. Medical progress moyamoya disease and moyamoya syndrome. N. Engl. J. Med. 360, 1226\u20131237. https:\/\/doi.org\/10.1056\/NEJMra0804622 (2009).","journal-title":"N. Engl. J. Med."},{"key":"99009_CR10","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1161\/Strokeaha.114.005624","volume":"45","author":"WS Cho","year":"2014","unstructured":"Cho, W. S. et al. Long-term outcomes after combined revascularization surgery in adult moyamoya disease. Stroke 45, 3025. https:\/\/doi.org\/10.1161\/Strokeaha.114.005624 (2014).","journal-title":"Stroke"},{"key":"99009_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1161\/Strokeaha.113.004386","volume":"45","author":"S Miyamoto","year":"2014","unstructured":"Miyamoto, S. et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease results of the japan adult moyamoya trial. Stroke 45, 1415\u20131421. https:\/\/doi.org\/10.1161\/Strokeaha.113.004386 (2014).","journal-title":"Stroke"},{"key":"99009_CR12","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan, W. N. et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 45, 2160\u20132236. https:\/\/doi.org\/10.1161\/STR.0000000000000024 (2014).","journal-title":"Stroke"},{"key":"99009_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.10.003","volume":"25","author":"S Yamada","year":"2016","unstructured":"Yamada, S. et al. Effects of surgery and antiplatelet therapy in ten-year follow-up from the registry study of research committee on moyamoya disease in Japan. J. Stroke Cerebrovasc. 25, 340\u2013349. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2015.10.003 (2016).","journal-title":"J. Stroke Cerebrovasc."},{"key":"99009_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009942","author":"D Onozuka","year":"2016","unstructured":"Onozuka, D. et al. Prehospital antiplatelet use and functional status on admission of patients with non-haemorrhagic moyamoya disease: A nationwide retrospective cohort study (J-ASPECT study). BMJ Open https:\/\/doi.org\/10.1136\/bmjopen-2015-009942 (2016).","journal-title":"BMJ Open"},{"key":"99009_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017701","volume":"10","author":"WK Seo","year":"2021","unstructured":"Seo, W. K. et al. Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J. Am. Heart Assoc. 10, e017701. https:\/\/doi.org\/10.1161\/JAHA.120.017701 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"99009_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.608000","volume":"11","author":"F Ye","year":"2020","unstructured":"Ye, F. et al. Efficacy and safety of antiplatelet agents for adult patients with ischemic moyamoya disease. Front. Neurol. 11, 608000. https:\/\/doi.org\/10.3389\/fneur.2020.608000 (2020).","journal-title":"Front. Neurol."},{"key":"99009_CR17","first-page":"110","volume":"30","author":"YW Chan","year":"1993","unstructured":"Chan, Y. W. & Kay, C. S. Pentoxifylline in the treatment of acute ischaemic stroke\u2014A reappraisal in Chinese stroke patients. Clin. Exp. Neurol. 30, 110\u2013116 (1993).","journal-title":"Clin. Exp. Neurol."},{"key":"99009_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1161\/01.str.27.6.1099","volume":"27","author":"H Nishimura","year":"1996","unstructured":"Nishimura, H., Naritomi, H., Iwamoto, Y., Tachibana, H. & Sugita, M. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Stroke 27, 1099\u20131103. https:\/\/doi.org\/10.1161\/01.str.27.6.1099 (1996) (discussion 1104).","journal-title":"Stroke"},{"key":"99009_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s12035-016-9739-z","volume":"54","author":"HP Huang","year":"2017","unstructured":"Huang, H. P. et al. Comparative efficacy and safety of nine anti-platelet therapies for patients with ischemic stroke or transient ischemic attack: A mixed treatment comparisons. Mol. Neurobiol. 54, 1456\u20131466. https:\/\/doi.org\/10.1007\/s12035-016-9739-z (2017).","journal-title":"Mol. Neurobiol."},{"key":"99009_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/01.STR.0000063141.24491.50","volume":"34","author":"J Matias-Guiu","year":"2003","unstructured":"Matias-Guiu, J. et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: A randomized, double-blind, multicenter trial. Stroke 34, 840\u2013848. https:\/\/doi.org\/10.1161\/01.STR.0000063141.24491.50 (2003).","journal-title":"Stroke"},{"key":"99009_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"Antithrombotic Trialists' Collaboration","year":"2009","unstructured":"Antithrombotic Trialists\u2019 Collaboration et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849\u20131860. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1 (2009).","journal-title":"Lancet"},{"key":"99009_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","volume":"7","author":"Y Huang","year":"2008","unstructured":"Huang, Y. et al. Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study. Lancet Neurol. 7, 494\u2013499. https:\/\/doi.org\/10.1016\/S1474-4422(08)70094-2 (2008).","journal-title":"Lancet Neurol."},{"key":"99009_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","volume":"359","author":"RL Sacco","year":"2008","unstructured":"Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238\u20131251. https:\/\/doi.org\/10.1056\/NEJMoa0805002 (2008).","journal-title":"N. Engl. J. Med."},{"key":"99009_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2211","volume":"365","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: Open label, blinded endpoint, randomised controlled phase II trial. BMJ 365, l2211. https:\/\/doi.org\/10.1136\/bmj.l2211 (2019).","journal-title":"BMJ"},{"key":"99009_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5108","volume":"363","author":"Q Hao","year":"2018","unstructured":"Hao, Q. et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: Systematic review and meta-analysis. BMJ 363, k5108. https:\/\/doi.org\/10.1136\/bmj.k5108 (2018).","journal-title":"BMJ"},{"key":"99009_CR26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/01.STR.0000177872.87960.61","volume":"36","author":"M Uyttenboogaart","year":"2005","unstructured":"Uyttenboogaart, M., Stewart, R. E., Vroomen, P. C., De Keyser, J. & Luijckx, G. J. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke 36, 1984\u20131987. https:\/\/doi.org\/10.1161\/01.STR.0000177872.87960.61 (2005).","journal-title":"Stroke"},{"key":"99009_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/2017.9.Jns17576","volume":"130","author":"T Funaki","year":"2019","unstructured":"Funaki, T. et al. High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: Analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. J. Neurosurg. 130, 525\u2013530. https:\/\/doi.org\/10.3171\/2017.9.Jns17576 (2019).","journal-title":"J. Neurosurg."},{"key":"99009_CR28","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3171\/2018.10.JNS181139","volume":"132","author":"T Funaki","year":"2019","unstructured":"Funaki, T. et al. Effect of choroidal collateral vessels on de novo hemorrhage in moyamoya disease: Analysis of nonhemorrhagic hemispheres in the Japan Adult Moyamoya Trial. J. Neurosurg. 132, 408\u2013414. https:\/\/doi.org\/10.3171\/2018.10.JNS181139 (2019).","journal-title":"J. Neurosurg."},{"key":"99009_CR29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3171\/2015.6.Jns151105","volume":"124","author":"T Kim","year":"2016","unstructured":"Kim, T. et al. Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia. J. Neurosurg. 124, 1788\u20131793. https:\/\/doi.org\/10.3171\/2015.6.Jns151105 (2016).","journal-title":"J. Neurosurg."},{"key":"99009_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.wneu.2016.04.083","volume":"92","author":"H Sun","year":"2016","unstructured":"Sun, H. et al. Perioperative complications and long-term outcomes after bypasses in adults with moyamoya disease: A systematic review and meta-analysis. World Neurosurg. 92, 179\u2013188. https:\/\/doi.org\/10.1016\/j.wneu.2016.04.083 (2016).","journal-title":"World Neurosurg."},{"key":"99009_CR31","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000007819","volume":"93","author":"D Herve","year":"2019","unstructured":"Herve, D. et al. Predictors of clinical or cerebral lesion progression in adult moyamoya angiopathy. Neurology 93, e388\u2013e397. https:\/\/doi.org\/10.1212\/WNL.0000000000007819 (2019).","journal-title":"Neurology"},{"key":"99009_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3171\/2014.10.Jns132369","volume":"122","author":"XJ Liu","year":"2015","unstructured":"Liu, X. J. et al. Clinical features and long-term outcomes of moyamoya disease: A single-center experience with 528 cases in China. J. Neurosurg. 122, 392\u2013399. https:\/\/doi.org\/10.3171\/2014.10.Jns132369 (2015).","journal-title":"J. Neurosurg."},{"key":"99009_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1161\/Strokeaha.106.478297","volume":"38","author":"S Kuroda","year":"2007","unstructured":"Kuroda, S., Hashimoto, N., Yoshimoto, T. & Iwasaki, Y. Radiological findings, clinical course, and outcome in asymptomatic Moyamoya disease\u2014Results of multicenter survey in Japan. Stroke 38, 1430\u20131435. https:\/\/doi.org\/10.1161\/Strokeaha.106.478297 (2007).","journal-title":"Stroke"},{"key":"99009_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1331.2011.03481.x","volume":"19","author":"M Kraemer","year":"2012","unstructured":"Kraemer, M., Berlit, P., Diesner, F. & Khan, N. What is the expert\u2019s option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey. Eur. J. Neurol. 19, 163\u2013167. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03481.x (2012).","journal-title":"Eur. J. Neurol."},{"key":"99009_CR35","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.030","volume":"27","author":"K Oki","year":"2018","unstructured":"Oki, K. et al. Trends of antiplatelet therapy for the management of moyamoya disease in Japan: Results of a nationwide survey. J. Stroke Cerebrovasc. 27, 3605\u20133612. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.08.030 (2018).","journal-title":"J. Stroke Cerebrovasc."},{"key":"99009_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1227\/Neu.0000000000001354","volume":"80","author":"WS Cho","year":"2017","unstructured":"Cho, W. S. et al. Can combined bypass surgery at middle cerebral artery territory save anterior cerebral artery territory in adult moyamoya disease?. Neurosurgery 80, 431\u2013437. https:\/\/doi.org\/10.1227\/Neu.0000000000001354 (2017).","journal-title":"Neurosurgery"},{"key":"99009_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.5124\/jkma.2019.62.11.577","volume":"62","author":"JE Kim","year":"2019","unstructured":"Kim, J. E. & Pang, C. H. Diagnosis and treatment of adult Moyamoya disease. J. Korean Med. Assoc. 62, 577\u2013585. https:\/\/doi.org\/10.5124\/jkma.2019.62.11.577 (2019).","journal-title":"J. Korean Med. Assoc."},{"key":"99009_CR38","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/01616412.2019.1580455","volume":"41","author":"S Ando","year":"2019","unstructured":"Ando, S. et al. Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: Subanalysis of a prospective cohort. Neurol. Res. 41, 480\u2013487. https:\/\/doi.org\/10.1080\/01616412.2019.1580455 (2019).","journal-title":"Neurol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99009-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99009-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:13:23Z","timestamp":1670084003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99009-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99009"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99009-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant number : HI17C1561). The authors declare no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. No benefits of any form have been or will be received from any commercial party directly or indirectly related to the subject of this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19367"}}